Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26250780 | 0.91 | CRBN (0.53) | CRBNDDB1IKZF2 | |
| SCHEMBL24861079 | 0.89 | CRBN (0.41) | CRBNDDB1 | |
| SCHEMBL26248314 | 0.83 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL26247581 | 0.83 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL26248254 | 0.83 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL24861377 | 0.83 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL31538742 | 0.80 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL26250141 | 0.80 | CRBN (0.72) | CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL31330885 | 0.80 | SLC6A2 (0.46) | CRBNDDB1 | |
| SCHEMBL31091770 | 0.80 | CRBN (0.45) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384756-B2 | Piperidinedione derivatives | INNOCURE THERAPEUTICS, INC. (KR) | 2025-08-12 | — | — | US | claimed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4624472-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| CN-116323619-A | Piperidinedione derivatives | 因诺库尔治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4116298-A1 | PIPERIDINEDIONE DERIVATIVE | Innocure Therapeutics, Inc. (KR) | 2023-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, CUL1, PSMB10 | CRBN 1/4885DDB1 868/4885IKZF2 86/4885 |
| US-12384756-B2 | Piperidinedione derivatives | CRBN, CUL1, PSMB10 | CRBN 1/4885DDB1 868/4885IKZF2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.